[PDF][PDF] KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition

Y Pan, H Han, H Hu, H Wang, Y Song, Y Hao, X Tong… - Cancer Cell, 2023 - cell.com
Lung squamous cell carcinoma (LUSC) represents a major subtype of lung cancer with
limited treatment options. KMT2D is one of the most frequently mutated genes in LUSC (> …

Targeting HER2 Exon 20 Insertion–Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib

H Han, S Li, T Chen, M Fitzgerald, S Liu, C Peng… - Cancer research, 2021 - AACR
No targeted treatments are currently approved for HER2 exon 20 insertion–mutant lung
adenocarcinoma patients. Mobocertinib (TAK-788) is a potent irreversible tyrosine kinase …

Loss of TSC1/TSC2 sensitizes immune checkpoint blockade in non–small cell lung cancer

Q Huang, F Li, H Hu, Z Fang, Z Gao, G Xia, WL Ng… - Science …, 2022 - science.org
Tuberous sclerosis complex subunit 1 (TSC1) and 2 (TSC2) are frequently mutated in non–
small cell lung cancer (NSCLC), however, their effects on antitumor immunity remained …

Targeting the Atf7ip–Setdb1 Complex Augments Antitumor Immunity by Boosting Tumor Immunogenicity

H Hu, A Khodadadi-Jamayran, I Dolgalev, H Cho… - Cancer Immunology …, 2021 - AACR
Substantial progress has been made in understanding how tumors escape immune
surveillance. However, few measures to counteract tumor immune evasion have been …

[HTML][HTML] Nemvaleukin alfa, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancer

Y Pan, Y Hao, H Han, T Chen, H Ding… - … for immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Background Small cell lung cancer (SCLC) is a deadly disease with a 5-year survival of less
than 7%. The addition of immunotherapy to chemotherapy was recently approved as first …

[HTML][HTML] Histone Deacetylase 6 Inhibition Exploits Selective Metabolic Vulnerabilities in LKB1 Mutant, KRAS Driven NSCLC

H Zhang, CS Nabel, D Li, RÍ O'Connor… - Journal of Thoracic …, 2023 - Elsevier
Abstract Introduction In KRAS-mutant NSCLC, co-occurring alterations in LKB1 confer a
negative prognosis compared with other mutations such as TP53. LKB1 is a tumor …

Prolactin Induced Protein (PIP) is a potential biomarker for early stage and malignant breast cancer

A Gangadharan, T Nyirenda, K Patel… - The Breast, 2018 - Elsevier
Objectives Breast cancer (BC) is the second leading cause of cancer-related mortality in
women. Bioinformatic analysis and expression screening showed that Prolactin Induced …

Benefits of Telehealth across different socio-economic communities

G Lakenauth, S Tang - IEEE Long Island Systems, Applications …, 2014 - ieeexplore.ieee.org
Vital Care Services (VICS) is a Telehealth servicing company which addresses the national
healthcare issue by providing cost effective health and wellness solutions to patients …